{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:00:30Z","timestamp":1785308430214,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PD is still managed symptomatically with levodopa, and no disease-modifying therapy is available, making effective treatment difficult. In recent years, preclinical and some clinical evidence have shown that glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists, GLP-1 RAs) can cross to varying degrees the blood\u2013brain barrier and exert neuroprotective effects, including anti-inflammatory, antioxidant, and insulin-sensitizing actions. They also reduce pathological protein aggregation, regulate mitochondrial function, and enhance autophagy, demonstrating their therapeutic potential for PD. Therefore, systematically reviewing the research status, hotspots, and trends of GLP-1 receptor agonists in PD is crucial for understanding the dynamic development of this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches were performed in the Web of Science Core Collection and Scopus databases to identify literature on GLP-1 receptor agonists and PD. Bibliometric analyses were conducted using CiteSpace and VOSviewer to evaluate publication trends, collaborative networks, co-citation patterns, and research hotspots. The search period spanned from database inception to April 14, 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 282 articles from WoS and Scopus were included for bibliometric analysis. The top three countries are China, the United States, and the United Kingdom. Major institutions include University College London, Shanxi Medical University, Henan University of Chinese Medicine, and Lancaster University, with authors H\u00f6lscher, Athauda, Aviles-Olmos, and Li. Hotspots focus on oxidative stress, insulin resistance, alpha-synuclein, blood\u2013brain barrier, and exendin-4. Emerging themes with increasing research attention include mild cognitive impairment, GIP\/GLP-1 dual agonists, and blood\u2013brain barrier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PD is a multifactorial neurodegenerative disorder characterized by complex and heterogeneous pathological mechanisms, supporting the exploration of multi-target therapeutic strategies. GLP-1 receptor signaling is widely distributed in the central nervous system and peripheral metabolic tissues, suggesting a potential link between metabolic regulation and neurodegenerative processes. Bibliometric analysis indicates that GLP-1 receptor agonists have attracted increasing research attention in PD, particularly in relation to metabolic dysfunction, neuroinflammation, and mitochondrial pathways. However, current clinical evidence remains inconsistent, with findings influenced by drug heterogeneity, study populations, and methodological differences. Overall, GLP-1 receptor\u2013related mechanisms represent an emerging and evolving research direction in PD, warranting further experimental and clinical investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/osf.io\/u7wdy<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2026.1894856","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:03:30Z","timestamp":1785305010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson\u2019s disease: a bibliometric analysis"],"prefix":"10.3389","volume":"20","author":[{"given":"Ting","family":"Yu","sequence":"first","affiliation":[{"name":"Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen","place":["Guangdong, China"]},{"name":"School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Mai","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen","place":["Guangdong, China"]},{"name":"School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou","place":["Fujian, China"]},{"name":"Shenzhen Clinical College of Integrated Traditional Chinese and Western Medicine, Affiliated to Guangzhou University of Chinese Medicine, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenzhen Clinical College of Integrated Traditional Chinese and Western Medicine, Affiliated to Guangzhou University of Chinese Medicine, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Pan","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Kuang","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen","place":["Guangdong, China"]},{"name":"School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou","place":["Fujian, China"]},{"name":"Shenzhen Clinical College of Integrated Traditional Chinese and Western Medicine, Affiliated to Guangzhou University of Chinese Medicine, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial.","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10654-023-00970-0","article-title":"Diabetes mellitus, prediabetes and the risk of parkinson\u2019s disease: A systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases.","volume":"38","author":"Aune","year":"2023","journal-title":"Eur. J. Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with parkinson\u2019s disease.","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11892-025-01606-1","article-title":"Targeting metabolic dysfunction in parkinson\u2019s disease: The role of GLP-1 agonists in body weight regulation and neuroprotection.","volume":"25","author":"Aviles-Olmos","year":"2025","journal-title":"Curr. Diab. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight.","volume":"124","author":"Baggio","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"113693","DOI":"10.1016\/j.expneurol.2021.113693","article-title":"An extended release GLP-1 analogue increases \u03b1-synuclein accumulation in a mouse model of prodromal parkinson\u2019s disease.","volume":"341","author":"Bergkvist","year":"2021","journal-title":"Exp. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease.","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2015.11.007","article-title":"Risk and course of motor complications in a population-based incident parkinson\u2019s disease cohort.","volume":"22","author":"Bjornestad","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of parkinson\u2019s disease: A cohort study of patients with diabetes.","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.NT.0000803396.74436.40","article-title":"Highlights of the AAN updated guideline on treating motor symptoms in early Parkinson\u2019s disease.","volume":"21","author":"Cajigal","year":"2021","journal-title":"Neurol. Today"},{"key":"B11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/antiox12040955","article-title":"Oxidative stress and neuroinflammation in parkinson\u2019s disease: The role of dopamine oxidation products.","volume":"12","author":"Chakrabarti","year":"2023","journal-title":"Antioxidants"},{"key":"B12","doi-asserted-by":"publisher","first-page":"108028","DOI":"10.1016\/j.maturitas.2024.108028","article-title":"Unlocking longevity with GLP-1: A key to turn back the clock?","volume":"186","author":"Chavda","year":"2024","journal-title":"Maturitas"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: Progressive knowledge domain visualization.","volume":"101","author":"Chen","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/ijo.2015.136","article-title":"Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.","volume":"39","author":"Christensen","year":"2015","journal-title":"Int. J. Obes."},{"key":"B15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial.","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/wnl.0000000000005771","article-title":"Association between diabetes and subsequent parkinson disease: A record-linkage cohort study.","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: A proof-of-concept clinical trial.","volume":"47","author":"Dei Cas","year":"2024","journal-title":"J. Endocrinol. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","article-title":"Dual GLP-1 and GIP agonist tirzepatide exerted neuroprotective action in a parkinson\u2019s disease rat model.","volume":"16","author":"Delvadia","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases.","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1537898","DOI":"10.3389\/fnins.2025.1537898","article-title":"Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus.","volume":"19","author":"Dou","year":"2025","journal-title":"Front. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1.","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70075","DOI":"10.1111\/ene.70075","article-title":"GLP-1 agonists as potential neuromodulators in development of parkinson\u2019s disease: A nationwide cohort study.","volume":"32","author":"Gamborg","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in parkinson\u2019s disease: An updated comprehensive systematic review with meta-analysis.","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: Role in neurodegenerative disease and potential for targeting.","volume":"29","author":"H\u00f6lscher","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","article-title":"Incretin hormones GLP-1 and GIP normalize energy utilization and reduce inflammation in the brain in alzheimer\u2019s disease and parkinson\u2019s disease: From repurposed GLP-1 receptor agonists to novel dual GLP-1\/GIP receptor agonists as potential disease-modifying therapies.","volume":"39","author":"H\u00f6lscher","year":"2025","journal-title":"CNS Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease.","volume":"31","author":"Hong","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10401","DOI":"10.2147\/IJN.S479670","article-title":"Exenatide-modified deferoxamine-based nanoparticles ameliorates neurological deficits in Parkinson\u2019s disease mice.","volume":"19","author":"Huang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease by increasing expression of BNDF.","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrneurol.2015.249","article-title":"Evolving basic, pathological and clinical concepts in PD.","volume":"12","author":"Kalia","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jdi.12464","article-title":"Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist.","volume":"7","author":"Katsurada","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"B32","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biom14070872","article-title":"Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration.","volume":"14","author":"Kopp","year":"2024","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1017\/S109285292510031X","article-title":"Glucagon-like peptide-1 receptor agonists for the prevention and treatment of Parkinson\u2019s disease.","volume":"30","author":"Lee","year":"2025","journal-title":"CNS Spectr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"697440","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u03b1-synuclein and oxidative stress.","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"109946","DOI":"10.1016\/j.neuropharm.2024.109946","article-title":"GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and Parkinsonian mice.","volume":"252","author":"Liu","year":"2024","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease.","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1664269","DOI":"10.3389\/fnagi.2025.1664269","article-title":"Parkinson\u2019s disease physiopathology\u2014beyond the \u03b1-synuclein aggregation: A narrative review.","volume":"17","author":"Macedo","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early parkinson\u2019s disease.","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: Impacts and mechanisms throughout Parkinson\u2019s disease progression.","volume":"132","author":"Riederer","year":"2025","journal-title":"J. Neural Transm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"110643","DOI":"10.1016\/j.neuropharm.2025.110643","article-title":"Exendin-4 protects the dopaminergic neurons by attenuating inflammatory responses of microglial cells via activation of AMPK.","volume":"279","author":"Rimal","year":"2025","journal-title":"Neuropharmacology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics.","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1007\/s00210-025-03920-7","article-title":"Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.","volume":"398","author":"Salem","year":"2025","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1210\/endo-121-3-1076","article-title":"Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.","volume":"121","author":"Shimizu","year":"1987","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1017\/neu.2026.10060","article-title":"The effect of GLP-1 receptor agonists on autophagy: Insights gathered from research evaluating neurodegenerative disorders with these agents.","volume":"38","author":"Sioufi","year":"2026","journal-title":"Acta Neuropsychiatr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00702-025-02882-7","article-title":"Impact of diabetes mellitus type two on incidence and progression of parkinson\u2019s disease: A systematic review of longitudinal patient cohorts.","volume":"132","author":"Stockmann","year":"2025","journal-title":"J. Neural Transm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: Modelling study of global burden of disease study 2021.","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with parkinson\u2019s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12929-024-01025-6","article-title":"Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.","volume":"31","author":"Wang","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of parkinson\u2019s disease.","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinson\u2019s Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JPD-191768","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of parkinson\u2019s disease.","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Parkinson\u2019s Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00415-025-13301-y","article-title":"Clinical efficacy of GLP-1 receptor agonists in the treatment of parkinson\u2019s disease: A systematic review and meta-analysis of randomized controlled trials.","volume":"272","author":"Zhang","year":"2025","journal-title":"J. Neurol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1894856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:03:31Z","timestamp":1785305011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1894856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":53,"alternative-id":["10.3389\/fnins.2026.1894856"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1894856","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1894856"}}